A Novel remedy for periodontal bone loss

Abstract Periodontitis is a common chronic inflammatory disease characterized by destruction of the supporting structures of the teeththe periodontal ligament and alveolar boneThe total prevalence of periodontitis in adults agedyears and older wasrepresenting aboutmillion adults agedyears and olderandin adults agedyears and older in the U SEpidemiological data confirm that diabetes is a major risk factor for periodontitissusceptibility to periodontitis is approximately fivefold higher in people with diabetesIn the USA alonemillion peopleof the U Spopulationhave diabetesCurrently worldwide diabetic population stands atmillion and it is estimated that bythis number will increase tomillionPeriodontitis is highly prevalent in diabetes and has multiple negative impacts on quality of lifeThe current treatment option for periodontal diseases involves mechanical debridementscaling and root planning and sometime followed by adjunctive therapy such as local delivery of antimicrobialse gPeriochipor systemic antibiotics such as doxycyclineThe antimicrobialsdisadvantages includeantimicrobial resistancefailure to penetrate beyond biofilm surface layerand systemic side effectsSurgical treatment is painful and requires frequent and multiple visits to the dentistOther limitation of current treatment is that none of these drugs are targeting host and periodontal bone lossThere is a major void in periodontal disease therapeutics products which can target host response and easy to useThe global periodontal disease therapeutics market is anticipated to gain a growth offromtoAt this pacethe market is estimated to reach a valuation of US$M by the end of the forecast periodPeriomics Care is an early stage New York based biotechnology company that was established to commercialize a novel oral strip or gel formulation for treatment of periodontal disease specifically for Typediabetic populationWith NYU College of DentistryPeriomics Care propose to develop sustained release antagonist formulation to target succinate receptorSucnRthe method is protected by provisional US patentThe premise of this proposal is based on our recent findings that succinatea Krebs cycle intermediate is elevated in diabetes and activates SucnRto stimulate osteoclastogenesisWe further demonstrated that blocking SucnRactivation by a synthetic antagonist controls inflammation and periodontal bone lossWe proposed to develop strip film and gel formulations based on biodegradable material impregnated with SucrRantagonist which can be implanted by dentist or used as local tropical gel over gingival tissue by consumersThe funds gained from this STTR grant will be used todevelop and optimize the formulationtest and determine the efficacy of the formulation in periodontal animal modelThe outcomes from this study will help the company move the optimal formulation into Phase II translational studies for treatment and prevention of periodontal disease Project Narrative Periodontal disease cause functional limitation and impact is significantly associated with ageMoreover chronic periodontal disease is associated with other systemic diseaseThe treatment options are invasivepainful and not always successful which results in tooth lossThe impact to society is burdensome as patients suffer a compromised life qualityThe development of a biodegradable oral strip or gel formulation that could be administered through less invasive approaches to augment or replace the conventional treatment could prove to be a major step forward in the treatment of periodontal disease